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http://dx.doi.org/10.1016/j.stemcr.2016.07.024SUMMARYThe challenges to effective drug delivery to brain tumors are twofold: (1) there is a lack of non-invasive methods of local delivery and (2)
the blood-brain barrier limits systemic delivery. Intranasal delivery of therapeutics to the brain overcomes both challenges. In mouse
model of malignant glioma, we observed that a small fraction of intranasally delivered neural stem cells (NSCs) can migrate to the brain
tumor site. Here, we demonstrate that hypoxic preconditioning or overexpression of CXCR4 significantly enhances the tumor-targeting
ability of NSCs, but without altering their phenotype only in geneticallymodified NSCs. ModifiedNSCs deliver oncolytic virus to glioma
more efficiently and extend survival of experimental animals in the context of radiotherapy. Our findings indicate that intranasal deliv-
ery of stem cell-based therapeutics could be optimized for future clinical applications, and allow for safe and repeated administration of
biological therapies to brain tumors and other CNS disorders.INTRODUCTION
Malignant gliomas (MGs), a group of high-grade primary
adult brain tumors, are classically known for being highly
aggressive and incurable. With an average median survival
of only 14.6months following the current standard-of-care
treatment regimen,MGs are in desperate need of novel and
effective treatment strategy (Stupp et al., 2005). The blood-
brain barrier (BBB) renders several highly effective systemic
chemotherapeutic agents ineffective in the setting of MGs
(Lesniak and Brem, 2004; Lesniak et al., 2001). Along with
presence of the BBB there are several other intrinsic tumor
characteristics that orchestrate the eventual failure of the
current standard of care, such as inherent resistance of
tumor cells to chemotherapeutic agents (Decleves et al.,
2006; Tian et al., 2015), complex interplay between radia-
tion and hypoxia that results in radioresistance (Dahan
et al., 2014; Moeller et al., 2004; Vordermark et al., 2004),
and the fluid phenotype of cancer cells that seamlessly
transition between differentiated and dedifferentiated
forms following chemotherapy (Auffinger et al., 2014;
Safa et al., 2015).
The particular anatomy of the olfactory and trigeminal
neural pathways connects the nasal mucosa directly with
the brain and the perivascular pathway by circumventing
theBBB (Jianget al., 2015).Using intranasaldelivery, several
therapeutic agents, such as small molecules, proteins, hor-
mones, and nanoparticles, have been shown to successfully
reach the brain (Andrade, 2015; Elnaggar et al., 2015; FengStem Cell Repo
This is an open access article under the Cet al., 2012; Kim et al., 2012). The intranasal route has also
been explored for delivering larger cell-based carriers such
asmesenchymal stemcells (MSCs) in the settingof ischemic
brain injury and Parkinson’s disease (Danielyan et al., 2011;
vanVelthoven et al., 2010). Reitz et al. (2012) demonstrated
that intranasally delivered neural stem cells (NSCs) localize
to the intracranial human or murine glioma xenografts in
mouse models. Furthermore, our group has shown that
therapeutic MSCs and NSCs when delivered to the nasal
cavity not only travel to intracranial tumors in mice, but
also prolong the animals’ survival (Balyasnikova et al.,
2014; Gutova et al., 2015). Further validation of intranasal
delivery of various therapeutics to the brain is of particular
interest in the context of MG.
One of the emerging front-runners of experimental
therapeutic options for targeting MG is virotherapy
whereby oncolytic viruses (OVs), such as CRAd-S-pK7 (Ula-
sov et al., 2007), selectively infect tumor cells and induce a
specific anti-glioma cytotoxic response. We have shown
that stem cells not only can efficiently deliver OVs to exper-
imental glioma (Ahmed et al., 2011b, 2013; Morshed et al.,
2015), but also delay the premature viral neutralization
by the host’s immune system (Ahmed et al., 2010). Intra-
nasal delivery of OVs loaded in stem cell carriers allows
for a non-invasive and repeatable treatment regimen,
although to date the feasibility of such an approach has
not investigated.
AsMGs are known for the presence of prominent intratu-
moral areas of hypoxia (Dey et al., 2014; Keunen et al.,rts j Vol. 7 j 471–482 j September 13, 2016 j ª 2016 The Author(s). 471
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2011; Pistollato et al., 2010; Womeldorff et al., 2014), hyp-
oxia-driven glioma-tropic NSCs (Zhao et al., 2008) can pro-
vide an optimal cell-based carrier for OV delivery. We had
previously demonstrated that hypoxia can enhance the
motility of NSCs, and CXCR4 overexpression is the main
mechanism contributing to this phenomenon. The expres-
sion of SDF-1, a CXCR4 ligand, is significantly associated
with the hypoxic environment of MG (Zhao et al., 2008).
We and others have also previously shown that SDF-1
expression is significantly higher in glioma tissue after radi-
ation therapy (Balyasnikova et al., 2014; Zhao et al., 2008).
Therefore, in this study we investigated whether CXCR4
overexpression on the surface of NSCs either by hypoxic
preconditioning or genetic modification of NSCs allows
for enhanced migratory properties, and the therapeutic
outcome of intranasal delivery of OV-loaded CXCR4-ex-
pressing NSCs in glioma-bearing mice.
We hypothesized that intranasal delivery of CXCR4-
expressing NSCs loaded with CRAd-S-pK7 will lead to tu-
mor-specific delivery of OV and increased survival in the
mouse model of glioma. Our results show that CXCR4-
enhanced NSCs possess higher motility toward SDF-1
gradient in vitro, delivered OV to glioma xenograft more
efficiently and provided a survival advantage to irradiated
mice bearing aggressive intracranial tumors. Moreover,
genetically modified NSCs would also retain their stemness
and genetic stability, making them a desirable cell carrier
for the intranasal delivery of therapeutics to theMG. These
studies establish an effective strategy to significantly
improve stem cell-based oncolytic virotherapy via selective
enhancement of tumor tropism signaling. Further refine-
ment and expansion strategies beyond the CXCR4/SDF-1
signaling axis should also be explored to optimize the clin-
ical translation value of this approach.RESULTS
Hypoxic Preconditioning Enhances the Tropism of
NSCs toward Glioma
The natural tumor tropism of stem cells is the foundation
for using NSCs as a therapeutic conduit to accomplish
targeted delivery of therapeutics (Ahmed et al., 2011a,
2013; Balyasnikova et al., 2014). The hypoxic environment
of glioma is thought to contribute to the mechanism of
NSC tropism (Zhao et al., 2008).
The migratory preference of NSCs toward glioma cell
lines were explored and defined for both NNSCs and HNSCs
via several in vitro assays. All assays consistently supported
the notion that HNSCs migrate faster toward glioma cells
and travel longer distances in a given time. In Figures 1A
and 1B, a transwell migration assay using tumor cells
grown as tumorspheres at the bottom of the dish shows472 Stem Cell Reports j Vol. 7 j 471–482 j September 13, 2016significantlymore GFP+ HNSCs that preferentiallymigrated
across the porous cell-culture inserts compared with GFP+
NNSCs (9.9% ± 0.8% of relative presence for HNSCs versus
0.4% ± 0.1% for NNSCs in GBM43 cultures, n = 5, ***p <
0.001; 64.9% ± 4.8% of relative presence for HNSCs versus
37.8% ± 8.0% for NNSCs in U87MG mCherry cultures,
n = 5, *p < 0.05). A similar outcome was observed for
collagen hydrogel cultures, where the separation between
tumor cells and the seeded GFP+ NSCs was achieved by a
layer of gelated hydrogel (Figure 1C). Within 12 hr, signif-
icantly more GFP+ HNSCs migrated to the bottom of the
dish across the gel layer (14 ± 2 HNSCs per visual field versus
8 ± 1 NNSCs for GBM43; 18 ± 2 HNSCs per visual field versus
9 ± 1 NNSCs for U87MG mCherry; n = 7, *p < 0.05). The
speed of migration toward glioma cells by GFP+ NSCs was
also determined to be faster (less time lapsed for the travel
between cell patches created by ibidi 2D silicone chambers)
based on live cell microscopy using the Olympus VivaView
microscope, in that HNSCs take significantly less time
to travel to the U87MG mCherry cells compared with
NNSCs (Figures S1A–S1C, 120 ± 12 min for HNSCs versus
220 ± 11 min for NNSCs; n = 6, *p < 0.001). Thus, these
data clearly indicate that hypoxic preconditioning signifi-
cantly increases tropism of NSCs toward patient-derived
GBM43 and U87MG cells growing as tumorspheres or as
attached cells, in agreement with previous observations
(Zhao et al., 2008).
Higher Surface Expression of CXCR4 in HNSCs and
CXCR4NSCs Drives Migration of NSCs toward SDF-1
Gradient In Vitro
We previously demonstrated that brain radiation therapy
(XRT) increases the expression of SDF-1 in U87MG xeno-
graft tumor (Balyasnikova et al., 2014), suggesting that
the CXCR4/SDF-1 signaling axis could potentially be uti-
lized to optimize tumor tropism of NSCs toward irradiated
glioma tissue. Here we show that hypoxia-treated NSCs
show about a 2-fold increase in the surface expression
of CXCR4 in HNSCs over NNSCs (Figure 2A; n = 3, *p <
0.0001) as determined by flow cytometry. Although
CXCR7, another receptor interacting with SDF-1, shows
hypoxia-induced surface expression in NSCs, the increase
in protein expression in HNSCs was <10% when compared
with NNSC controls (Figure S1C). Genetic modification
of NSCs via transduction with lentivirus encoding for
CXCR4, significantly increased mRNA CXCR4 expression
in CXCR4NSCs in comparison with cells transduced with
control lentivirus VCNSCs (n = 3, *p < 0.0001), as deter-
mined by qRT-PCR (Figure 2B). Nearly all transduced
NSCs were expressing CXCR4 on the cell surface as shown
by flow cytometry (Figure 2C), which is about 4 and 2.5
times higher than in NNSCs and HNSCs, respectively. These
results demonstrate that CXCR4 is a potential receptor
Figure 1. Hypoxia Pretreatment En-
hances Tropism of NSC toward Human
GBM Cells
(A and B) GFP+ NSCs treated with hypoxia
(HNSCs; 1% O2; 24 hr) or control NSCs
(NNSCs) were compared for ability to
migrate toward tumorspheres. HNSCs effec-
tively cross the culture insert membrane and
accumulate within tumorspheres of patient-
derived GBM43 glioma cells visualized with
DAPI nuclear stain (blue) (A) and U87MG
mCherry cells (B). Right panels represent
quantification of the relative presence of
GFP+ NSCs, indicating significantly higher
numbers of GFP+ HNSCs than NNSCs inside
the tumorspheres by 24 hr of co-culture
(n = 5, Student’s t test; ***p < 0.001
for GBM43, *p < 0.05 U87MG). Scale bars,
100 mm.
(C) Collagen hydrogel migration assay
further demonstrates the enhanced tumor
tropism by NSCs after hypoxia pretreatment;
Confocal z-stack 3D reconstruction shows
GFP+ NSCs (green) seeded on top of the
collagen hydrogel layer migrating to the
bottom of the culture dishes in both
GBM43blue (blue cells, top panels) and
U87MGmCherry adherent cultures (red cells,
bottom panel) by 12 hr. Quantification of
migrated GFP+ NSCs by microscopy visual
field (right) confirms the increased ‘‘hom-
ing’’ by HNSCs in both the GBM43blue and
U87MG mCherry cells after hypoxia pre-
treatment (n = 7; **p < 0.01, Student’s
t test, error bars with SEM).responsible for increased migration of NSCs toward glioma
tumors secreting SDF-1.
The higher CXCR4 expression in HNSCs and CXCR4NSCs
correlated with the increase in chemotaxis toward SDF-1
gradient in 3D migration assays (Figure 3A). Specifically,
HNSCs demonstrated a significantly increased migration
distance in response to SDF-1 stimulation (10 ng) upon
24 hr of hypoxia treatment (79 ± 19 pixels; n = 30 cells)
compared with NNSCs (23 ± 2 pixels; n = 30; *p < 0.001).
Moreover, CXCR4NSCs showed significantly improved
migration over HNSCs within 24 hr toward the SDF-1-con-
taining reservoir (114 ± 28 pixels; n = 30, *p < 0.001). The
presence of blocking antibody against CXCR4 immuno-
globulin G, however, abolished the migration toward the
SDF-1 source for both HNSCs and CXCR4NSCs (Figure 3B),suggesting a key dependence on CXCR4 in SDF-1-induced
NSC migration.
Hypoxia induces a phenotypic shift toward neural pro-
genitors in NSCs, whereas genetic modification of NSCs
to overexpress CXCR4 does not change their phenotype.
To ensure that 1%hypoxic culture for 24hrdoesnotnega-
tively affect the therapeutic potentials ofNSCs, we conduct-
ed an analysis of mRNA and protein expression for markers
of stemness and differentiation by qRT-PCR, western blot-
ting, and immunocytochemistry (ICC). The mRNA expres-
sion for SOX2, hNESTIN,MUSASHI (markers of neural stem-
ness), bIII-TUBULIN, and GFAP (markers of differentiation)
were assessed by qRT-PCR (Figure 4A). Our results demon-
strate significant changes in stemness markers after 24 hr
of treatment with hypoxia, where hNESTIN mRNA levelsStem Cell Reports j Vol. 7 j 471–482 j September 13, 2016 473
Figure 2. Analysis of the Surface CXCR4
Receptor Expression in NSCs
(A) Hypoxia pretreatment increases the
surface CXCR4 receptor expression on NSCs
by over 2-fold in comparison with NSCs
growing under normoxic conditions (flow
cytometry).
(B) Overexpression of CXCR4 in genetically
modified NSCs demonstrated by analysis of
mRNA levels in vector control (VCNSCs) and
CXCR4NSCs (n = 3; ***p < 0.001, Student’s
t test, error bars with SEM).
(C) Flow cytometry confirms that majority of
CXCR4NSCs are positive for the surface CXCR4
expression, representing nearly 5- and 2.5-
fold higher CXCR4 expression levels than in
non-modified NSCs growing under normoxic
and hypoxic conditions, respectively.significantly increased (443 ± 36-fold increase over nor-
moxia; n = 3, ***p < 0.001), whereas SOX2 and MUSASHI
were significantly decreased (0.04 ± 0.04- and 0.33 ± 0.11-
fold respectively; n = 3, ***p < 0.001) in comparison with
normoxia, indicating a possible phenotypic shift toward
themoremotileneuralprogenitor stagesofNSCs.Moreover,
the neural differentiation marker bIII-TUBULIN was signifi-
cantly reduced (0.45 ± 0.10-fold; n = 3, ***p < 0.001) in com-
parison with normoxia. Worth noting is that the astroglial
marker GFAP (data not shown) mRNA was undetectable
under either normoxia or hypoxia treatments. ICC staining
for the definitive astroglial differentiation marker S100B
showed complete absence in NSCs under either condition,
confirming that hypoxic preconditioning did not induce
NSC differentiation toward astrocytes (Figure S2C). ICC for
stemness and differentiation marker expressions supports
the qRT-PCR results (Figures S2A–S2C). These observations
confirm that, while hypoxic preconditioning allows NSCs
to largely maintain their stem cell profiles, a phenotypic
shift toward hNESTIN+ neural progenitor stages with
reduced terminal differentiation potentials is the predomi-
nant outcome for 24-hr hypoxia exposure, in agreement
with the observed increase in motility and tumor tropism.
Consistentwith knowledge thathypoxia induces upregu-
lation of HIF1a, we observed the increase in HIF1a expres-
sion in hypoxia-treated NSCs, which was accompanied by
activation of signaling as judged by an increase in pAKT
(Figures S2D–S2F). Similar induction of pAKT was accom-
plished by treatment of NSCs with SDF-1. Both SDF-1 and
hypoxia-induced pAKT were partially blocked by the
CXCR4 receptor antagonist AMD3100, thus indicating a474 Stem Cell Reports j Vol. 7 j 471–482 j September 13, 2016CXCR4-dependent mechanism of activation of down-
stream signaling in hypoxia-treated cells. Hypoxia-induced
signaling within the NSCs can involve complex signaling
networks that are known to regulate the apoptosis, differ-
entiation, and migratory/metastatic behaviors of many
normal or cancerous cell types (Barriga et al., 2013; Guan
et al., 2015; Guo et al., 2014; Speth et al., 2014). In addition,
activation of HIF1a signaling in NSCs can trigger biological
events not consistentwith their intendeduse as therapeutic
carriers. Therefore, given the establishedCXCR4/SDF-1 axis
in tropism of NSCs toward glioma, it is of high interest
to examine whether modification of NSCs via ectopic over-
expression of CXCR4 results in phenotypic stability of
NSCs. The analysis of markers of stemness and differentia-
tion at mRNA and protein levels in CXCR4NSCs confirmed
that overexpression of CXCR4 minimally affected the
expression profiles of hNESTIN, SOX2, and bIII TUBULIN
in CXCR4NSCs. Importantly, cytogenetic analysis revealed
that CXCR4NSCs cells retain their normal karyotype after ge-
netic modification via lentiviral transduction (Figure 4D).
XRT Increases SDF-1 Expression in GBM43 Glioma
Xenografts
To confirm the potential significance of SDF-1 in contrib-
uting to migration of NSCs in vivo, we euthanized control
and XRT-treated mice and compared brain tissues for SDF-1
expression.TheanalysisofH&Estainingand ICCofbraintis-
sue sections from control and irradiated mice demonstrates
reduced tumor burden after XRT, and significantly increased
SDF-1 levelsat the tumorsitesafterXRTtreatment (Figure5A;
n = 22 sections from 3 animals/group, ***p < 0.001).
Figure 3. Migration of HNSCs and
CXCR4NSCs Depends on SDF-1 Gradient
(A) Using the 3D chemotaxis assay m
chamber slides, NSCs treated with hypoxic
culture, as well as NSCs overexpressing
CXCR4 receptors, demonstrate significantly
longer chemotactic migration distance
toward SDF-1 containing medium chamber
(n = 30 cells; ***p < 0.001, Student’s t test).
(B) The SDF-1-dependent chemotaxis was
abolished in both HNSCs and CXCR4NSCs as
demonstrated by blocking with anti-CXCR4
monoclonal antibody (n = 30; ***p < 0.001,
Student’s t test, error bars with SEM).Quantitative analysis for positive immunostaining demon-
strated a nearly 4-fold increase in XRT-treated mice versus
control animals (Figure 5B). These findings are in agreement
withourpreviousobservationof an increase inSDF-1expres-
sion in irradiated U87MG xenografts and highlight the
significance of utilizing the SDF-1/CXCR4 axis to advance
NCSs as therapeutic carriers to glioblastoma in conjunction
with XRT treatment (Balyasnikova et al., 2014).
Hypoxia-Treated NSCs Support the Loading and
Replication of CRAd-S-pK7
Propagation of OVs in NSCs (HB1.F3.CD cells) utilized in
this study have been extensively characterized by our
group (Ahmed et al., 2011a, 2011b, 2013). We have previ-
ously demonstrated that CRAd-S-pK7 can replicate in
NSCs as well as in glioblastoma multiforme (GBM) cells
both in vitro and in vivo. To evaluate whether hypoxia-
treated or genetically modified NSCs can effectively deliver
the OVs to the tumor, we first evaluated the replication of
OV in HNSCs or CXCR4NSCs in comparison with respective
controls (NNSCs, VCNSCs). NSCs were infected with CRAd-
S-pK7 at 50 viral particles per cell. Figures S3A and S3B show
that treated NSCs (HNSCs and CXCR4NSCs) maintain their
capacity for viral replication, albeit with mildly reduced
progeny release compared with respective controls. These
results confirm the ability of modified NSCs to serve as
carriers of OVs for therapeutic studies.
CXCR4NSCs EfficientlyDeliverOVs via Intranasal Route
to Patient-Derived Glioma Xenografts and Improve
Survival in a Mouse Model
Delivery of OVs to glioma in vivo throughNSCs (NSC-OVs)
depends on the efficient migration of NSCs toward the tu-
mors when injected via the intranasal route. To evaluate
whether HNSC-OV therapy provides survival benefits, we
tested two different patient-derived xenograft (PDX)
models (GBM43 and GBM6). Without XRT, there was no
survival benefit of HNSC-OV intranasal treatments (Fig-
ure S4A). Following the standardized treatment protocol,we established that a fractionated dose of XRT significantly
improves survival of mice with both GBM43 (extension of
9 days ofmedian survival over PBS only with XRT; n = 8 an-
imals/group, *p < 0.05, log-rank test) and GBM6 (extension
of 8 days of median survival over PBS only with XRT; n = 5,
*p < 0.05) intracranial xenografts (Figure 6A). Treatments
of NNSCs alone, OVs alone, or NNSC-OVs did not further
improve the survival of animals. However, mice treated
with HNSCs-OVs showed prolonged survival (median sur-
vival benefit of 5 days) in bothGBM43 (n = 8, *p < 0.05; Fig-
ure 6B) and GBM6 (n = 5, *p < 0.05) models (Figure S4B).
These data confirm our hypothesis that hypoxic precondi-
tioning of intranasally delivered NSCs not only enhances
tumor tropism andOVdelivery but also results in therapeu-
tic benefits in aggressive PDX models of GBMs.
The ability of CXCR4NSCs to deliver OV payload to tumor
burden in a GBM43 PDX model was also evaluated.
Control VCNSCs or CXCR4NSCs were loaded with OVs and
intranasally delivered in irradiated mice according to the
standardized regimen. Figure 6C shows that CXCR4NSC-
OV therapy significantly improves the survival of animals
in comparison with control VCNSC-OV. These results
demonstrate that CXCR4NSCs migrate toward glioma and
successfully deliver OVs, which translates into improved
survival in the PDX glioma model.
To further confirm that the observed therapeutic effect is
due to enhanced migration of HNSCs or CXCR4NSCs toward
tumor burden, we implanted GBM43 glioma cells in the
brain and the mice were randomized to designated treat-
ment groups. On the eighth day after tumor injection,
mice were subjected to XRT (2 Gy for 5 days), which was
followed by intranasal delivery of NNSC-OVs/HNSC–OVs
or VCNSCs/CXCR4NSCs. To evaluate the delivery efficiency
of OVs by NSCs to the tumor site, we stained brain tissue
sections for hexon proteins of viral capsid. As shown in Fig-
ure 7A, NNSCs delivered the OVs to glioma (arrows); more-
over, hexon immunostaining was nearly twice as high in
the HNSCs group, as determined by the hexon staining
measured as the mean fluorescence intensity in analyzedStem Cell Reports j Vol. 7 j 471–482 j September 13, 2016 475
Figure 4. Phenotypic Characterization of
NSCs after Hypoxic Culture or CXCR4 Re-
ceptor Genetic Enhancement Strategies
(A) Compared with normoxic culture, hyp-
oxic pretreatment for 24 hr led to signifi-
cant mRNA changes in stemness markers
such as human NESTIN (hNESTIN), SOX2, and
MUSASHI (n = 3; ***p < 0.001, Student’s
t test).
(B) In contrast, genetic enhancement of
CXCR4 receptors demonstrate comparable
mRNA levels of stemness markers, and
early-stage neural progenitor marker bIII
TUBULIN (n = 3; p > 0.05, Student’s t test).
(C) The analysis of hNESTIN, SOX2, and
bIII TUBULIN via western blotting demon-
strates that protein expression corresponds
to mRNA expression and shows no changes
after genetic modification of NSCs to over-
express CXCR4 receptor (n = 3; p > 0.05,
Student’s t test, error bars with SEM).
(D) Cytogenetic analysis of NSCs indicates
that CXCR4NSCs retain their normal karyo-
type after genetic enhancement of CXCR4
receptor, similarly to VCNSCs.tissue sections (n = 10 from 3 animals/group, ***p < 0.001).
Furthermore, staining of tissue sections for hexon after
CXCR4NSC-OV therapy also confirmed that the ability of
CXCR4NSC to deliver OVs to the tumor burden is substan-
tially improved in comparison with OV therapy delivered
by control VCNSCs (Figure 7B).DISCUSSION
In this study we explored the strategy of enhancing the
migratory phenotype of NSCs for intranasal delivery of476 Stem Cell Reports j Vol. 7 j 471–482 j September 13, 2016therapeutic cell carriers for the treatment of MG. This
approach is thought to overcome several hurdles that stand
in the way of an effective glioma-targeting treatment
regimen.We deliveredmultiple doses of hypoxia-precondi-
tioned NSCs loaded with OVs directly to the nasal cavity
of mice bearing intracranial tumors. Mice treated with
this modality had significant survival advantage over other
control groups. Furthermore, selective genetic enhance-
ment in NSC surface expression of CXCR4 receptor
mimics the beneficial impact of hypoxia on NSCmigration
without the hypoxia-associated phenotypic changes in
NSCs. Thus, stable genetic manipulation of NSCs can
Figure 5. Irradiation Increases SDF-1
Expression in GBM43 Xenograft
The analysis of H&E staining and immuno-
cytochemistry of brain tissue sections from
control and irradiated mice demonstrates
reduced tumor burden but increased SDF-1
levels at the tumor sites after XRT treatment.
(A) SDF-1 expression (green) is strongly
localized at the tumor site (white boxes)
after irradiation (2 Gy 3 5 days).
(B) Densitometry quantification of the
viewing fields demonstrates a 4-fold increase
in SDF-1 expression in XRT-treated animals in
comparison with control animals (n = 3 ex-
periments; ***p < 0.001, Student’s t test,
error bars with SEM).selectively augment their therapeutic functions against
GBM, while maintaining intracellular OV replication.
Intranasal delivery effectively addresses the issue of cir-
cumventing the BBB and allows for non-invasive repeated
dosing. Although this modality has been successfully uti-
lized for delivering a variety of growth factors, hormones,
and neuropeptides (Chapman et al., 2013) to the CNS,
the efficacy of this route to deliver cell-based carriers is still
in its early phase of exploration. As the tropism of NSCs to
intracranial glioma and other malignancies is well vali-
dated (Aboody et al., 2000; Gutova et al., 2015; Kanojia
et al., 2015), the intranasal delivery imposes strict require-
ments for fast migration of therapeutic cell carriers from
the nasal cavity to prevent rapid clearance from the nasal
cavity. In this respect,MSCs geneticallymodified to overex-
press CXCR4 have been shown to possess higher migratory
properties and therapeutic potential in an acute lung injury
model (Yang et al., 2015), better homing capacity to bone
marrow in irradiated mice (Chen et al., 2013), and mobili-
zation and enhanced neuroprotection in a rat cerebral
ischemia model (Yu et al., 2012). However, genetic modifi-
cation of NSCs to enhance their migration toward brain
malignancy has never previously been explored.
Non-immunogenic glioma-tropic NSCs have been
known to be an effective carrier of OVs (Ahmed et al.,
2011a) in the mouse model of glioma. A study by Zhao
et al. (2008) showed that hypoxia is a key factor in deter-
mining NSC tropism to glioma and that multiple signaling
pathways mediate this phenomenon. Several other studies
delineate a critical role of hypoxia in promoting survival
and increasing the motility and regenerative capacity of
stem cells (Rosova et al., 2008; Wang et al., 2013). In line
with the current literature, our results also show that hyp-
oxic preconditioning of NSCs results in an increasedmigra-
tory phenotype of the NSCs, in part due to enhanced
expression of CXCR4 on the cell surface, and allows for
efficient intracellular viral replication. However, hypoxicpreconditioning is known to initiate other changes in
signaling, leading to upregulation of numerous chemokine
receptors and proteins involved in migration of NSCs
(Zhao et al., 2008). In our study, hypoxia preconditioning
affectedmRNA expression of several stemness and differen-
tiation markers in NSCs. To overcome this limitation,
we generated genetically modified NSCs overexpressing
CXCR4, thus providing certainty to the fate of therapeutic
stem cells. Genetic modification of NSCs had no effect on
the NSC phenotype at either RNA or protein level and
allowed for effective viral replication. Moreover, CXCR4-
overexpressing NSCs demonstrated genetic stability as as-
sessed by cytogenetic analysis. CXCR4/SDF-1 interaction
is necessary for the migration of neural progenitors in the
developing brain (Li and Ransohoff, 2008). The binding
of SDF-1 to CXCR4 can lead to the activation of multiple
signaling pathways in the CNS, such as phosphatidylinosi-
tol 3-kinase-AKT,mitogen-activatedproteinkinase, andnu-
clear factor kB (Li andRansohoff, 2008).Migration is a com-
plex process involving cooperative signaling events. SDF-1/
CXCR4 has been shown to play a critical role inNSCmigra-
tion through activation of p38MAPK, PAXILLIN, and cJUN
(Imitola et al., 2004). These reports corroborate our data
demonstrating that overexpression of CXCR4 endows
increased migration ability to the HB1F3.CD cells.
MGs are known to secrete SDF-1, and radiation therapy
further increases SDF-1 levels (Bajetto et al., 2006; Balyasni-
kova et al., 2014; Wang et al., 2013). Thus, the CXCR4/
SDF-1 axis may be essential for increased NSC motility
toward GBM. Indeed, after radiation animals treated with
either HNSCs-OVs or CXCR4NSC-OVs demonstrated higher
presence of viral protein in the tumor vicinity and survived
significantly longer than animals treated with NNSCs-OVs
or VCNSCs-OVs. As radiation therapy is an integral part of
the current treatment regimen for MG, the strategy of
enhancing the chemotactic properties of NSCs viamodula-
tion of CXCR4 expression should be further explored inStem Cell Reports j Vol. 7 j 471–482 j September 13, 2016 477
Figure 6. Hypoxia Pretreatment and CXCR4 Overexpression in
NSCs Are Necessary for Effective Intranasal Delivery of OV-
Loaded NSCs in Irradiated Animals
(A) When given only PBS intranasally, radiation therapy signifi-
cantly enhanced survival of mice bearing aggressive patient-
derived GBM43 glioma xenografts (median survival increased by
9 days; n = 8 animals/group; ***p < 0.001, log-rank test).
(B) However, there was no further improvement in survival when
mice were treated with intranasal OV, NNSCs, or NNSCs + OV
following XRT treatment. Treatment of mice with OV-loaded HNSCs
resulted in significant improvement in the survival of mice (5 days;
n = 8; *p < 0.05, log-rank test) after irradiation.
(C) Significant improvement in survival of mice after XRT was also
achieved with OV-loaded genetically enhanced CXCR4NSCs (9 days of
median survival benefits; n = 8; **p = 0.0013, log-rank test).various therapeutic settings.We envision that an ideal clin-
ical timing for intranasal oncolytic therapy via CXCR4NSCs
would be following standard radiotherapy. The non-inva-
sive nature of intranasal delivery would allow for repeated
treatments. CXCR4NSCs can be prepared in large quantities
for clinical use, circumventing the logistically challenging
hypoxia pretreatment.
Given the high translational value of this approach, we
urge caution regarding the limitations of preclinical rodent
models. It is well known that normal and cancerous
mouse tissues are poorly permissive for OVs, and CRAds
are rapidly cleared in immunocompetent hosts, rendering
the immunocompetent mouse unsuitable for CRAd
studies. Although both cotton rat and Syrian hamster are
CRAd-permissive animal models with intact immune sys-
tems, no glioma models are currently available for studies
in these animals (Ahmed et al., 2010). Our previous studies478 Stem Cell Reports j Vol. 7 j 471–482 j September 13, 2016in the cotton rat model have demonstrated the improved
dissemination and persistence of OV by autologous stem
cells, which efficiently shielded virus and suppressed anti-
CRAd immune response, allowing us to project efficient
entry and propagation of CRAds in glioma cells in immu-
nocompetent hosts (Ahmed et al., 2010). Furthermore,
NSCs can successfully disseminate OV in the tumor envi-
ronment (Morshed et al., 2015), which results in superior
therapeutic outcome in comparison with CRAd virother-
apy alone (Ahmed et al., 2013). Lastly, the immune
response against OV in immunocompetent hosts (Jiang
et al., 2014)may assist in the bystander anti-glioma activity
of the proposed therapy.
Finally,we recognize that rodentmodels for intranasal de-
livery ofNSCshave intrinsic limitations, such as the relative
size and anatomical differences in the nasal and olfactory
systems between humans and mice. Despite differences in
the anatomy of the nasal cavity, larynx, and pharyngeal de-
tails (Harkema et al., 2006), the fundamental structures and
layouts of the olfactory systems are well preserved across
vertebrate species (Ache, 2010), offering a compelling basis
for extrapolating basic cellular and molecular phenomena
from rodent models to human scenarios. Unlike rodents,
humans do not rely on olfactory sensation for survival
and have smaller olfactory systems (3% of the nasal epithe-
lium is olfactory) (Harkema et al., 2006) compared with ro-
dents (50%) (Gross et al., 1982), which may imply that
intranasal deliverywould be a less effective route ofNSCen-
try in humans. However, the rodent olfactory nasal epithe-
lium surface area ranges between 125.5 ± 4.0 and 136.9 ±
7.3mm2 in adultmice (Gross et al., 1982), whereas humans
have about 500 mm2 on average (Harkema et al., 2006),
which might offer more entry access for NSCs. In addition,
trigeminal nerves offer additional entry routes for NSCs
into the brain (Dhuria et al., 2010). Furthermore, we will
be able to achieve more precise delivery of NSCs to the
cribriform plate using catheter-based delivery. However, to
truly understand the effectiveness of stem cell penetration
to the brain from the nasal cavity, studies in large animal
models such as monkey should be conducted.
Our study demonstrates that for intranasal delivery of
NSCs-OV to be efficacious, hypoxia preconditioning or
genetically engineering NSCs to overexpress CXCR4 is
required to further enhance the penetration of NSCs into
the brain. This corroborates our previous observation that
direct intratumoral delivery of NSCs loaded with OVs gen-
erates amore potent response than a distant site of delivery
(Ahmed et al., 2013) due to the lower number of NCSs
reaching the tumor from a distant site. Although both in-
tracavitary and intrathecal delivery of NSCs in the context
of brain tumor are clinically relevant, they are invasive and
do not lend themselves tomultiple dosing. The restrictions
of systemic delivery of therapeutic agents for brain tumor
Figure 7. Analysis of Staining for Expres-
sion of Viral Capsid Hexon Proteins in
GBM43 Xenograft Tissue from Mice Intra-
nasally Treated with OV-Loaded NSCs
Analysis of hexon immunofluorescence
staining (green spots, yellow arrows)
indicates significantly improved OV de-
livery to the tumor site (white dashed
outline) in mice treated with modified
NSCs.
(A) Hexon signal (green) is significantly
higher at the tumor site (staining for
hNESTIN, red) in tissue sections from
mice treated with CRAd-pk7-loaded HNSCs
in comparison with NNSCs (n = 10 sec-
tions from 3 animals/group; ***p <
0.001, Student’s t test).
(B) Using GBM43 cells expressing blue
fluorescent protein, we also demonstrate much improved OV delivery to the tumor site using CXCR4NSCs when compared with VCNSCs
(n = 10 sections from 3 animals/group; ***p < 0.001, Student’s t test, error bars with SEM).have been well documented in the literature, with a major
limitation being the phenomenon of first-pass clearance
(Lesniak and Brem, 2004). For similar reasons, we did not
consider the systemic route of delivery as viable for NSC-
based OV therapy due to the fast elimination of NSCs
from systemic circulation (Aboody et al., 2006), high up-
take of CRAd by liver tissue (Waddington et al., 2008),
and potential hepatotoxicity. Intranasal delivery is an
attractive alternative due to its non-invasive and repeatable
nature and its potential for targeting inoperable brain ma-
lignancies, such asmultiple brainmetastases or invasive tu-
mors.We hypothesize that CXCR4 enhancement would be
beneficial to all applicable routes of delivery, given that the
SDF-1 chemotaxis gradient derived from tumor growth and
heightened by radiotherapy may be established across the
CNS. Therefore, the development of strategies enhancing
the number of therapeutic NSCs arriving at the brain tumor
using the intranasal route should be further pursued.
In summary, the current report builds on our previous
validation of the intranasal delivery of stem cells as a
feasible route for anti-glioma therapy. Here we show that
NSCs can be repeatedly delivered intranasally to extend
the survival benefits of oncolytic virotherapy against gli-
oma in animalmodels.We identified that hypoxia pretreat-
ment of NSCs enhances the migratory potential of NSCs
via the SDF-1/CXCR4 signaling axis. Furthermore, NSCs
genetically modified to overexpress CXCR4 provide effi-
cient delivery of the OV payload to glioma, resulting in
significant survival benefits in conjunction with radio-
therapy. The strategy of intranasal delivery of various
therapeutics by potent stem cell carriers should be further
evaluated in the context of brain malignancies for future
transition to the clinic.EXPERIMENTAL PROCEDURES
See also Supplemental Experimental Procedures.
Cell Culture and Reagents
U87MG cells and human NSCs (HB1.F3.CD) were maintained
in DMEM (Corning) with 10% fetal bovine serum (FBS; Hyclone).
Patient-derived GBM43 and GBM6 glioma cells were routinely
maintained asmouse flank tumors, andwere subsequently isolated
and maintained in 10% FBS (Hyclone) DMEM (Sarkaria et al.,
2006) or in serum-free neurobasal medium supplemented with
B27, N2, basic fibroblast growth factor (20 ng/mL), and epidermal
growth factor (20 ng/mL; all reagents from Life Technologies).
CXCR4-overexpressing NSCs (CXCR4NSCs) were generated by
transduction of HB1.F3.CD cells with lentivirus encoding for
CXCR4 cDNA (GenTarget), along with vector-only control NSCs
(VCNSCs) from the same passage of NSCs.
Hypoxic Culture
NSCs were cultured in a humidified hypoxic gas flow chamber at
37C (Coy Laboratory Products) with sustained 1% O2 and 5%
CO2 for 24 hr (
HNSCs). Control NSCs were maintained under the
same culture condition but at atmospheric O2 levels (
NNSCs).
Loading of NSCs with Oncolytic Virus
The generation of replication competent adenoviral vector CRAd-
S-pk7, which contains the wild-type adenovirus replication pro-
tein E1A under the control of human survivin promoter, has
been previously described (Ulasov et al., 2007). For analysis of viral
replication and progeny release, NNSCs, HNSCs, VCNSCs, and
CXCR4NSCs were infected with 50 CRAd-S-pk7 particles/cell. After
1 hr of incubation, cells were washed three times to remove un-
bound viral particles and grown in fresh complete growth me-
dium. After 72 hr, cells and medium were collected and freeze-
thawed three times to release infectious progeny. Lysates wereStem Cell Reports j Vol. 7 j 471–482 j September 13, 2016 479
cleared by centrifugation and titrated over adherent HEK293 cells
with 10-fold dilution. After 48 hr, cells were fixed and stained for
viral hexon protein detection using an Adeno-X Rapid Titer Kit
(Clontech). The titration (i.e., infectious) units were calculated to
determine the viral progeny release.
Patient-Derived Xenograft Mouse Model of GBM
All protocols were approved by the Institutional Committee on
Animal Use at The University of Chicago. The surgical procedures
were conducted according to the NIH guidelines on the care and
use of laboratory animals. Six- to eight-week-old athymic nude
male mice were obtained from Harlan Laboratories and main-
tained in a pathogen-free facility. Mice were anesthetized with
ketamine-HCl (25 mg/mL)/xylazine (2.5 mg/mL) solution, and
GBM43 or GBM6 cells were injected in the mouse brain at 2 3
104 or 1 3 105 cells in 2.5 mL of sterile saline, respectively, using
the established procedure (Ahmed et al., 2013). Standard post-
surgery care was given following a protocol approved by the Insti-
tutional Animal Care and Use Committee.
Radiation Therapy and Intranasal Stem Cell Therapy
Select groups of glioma xenograft mouse models underwent XRT
as detailed in the Results section. Specifically, after ketamine and xy-
lazine anesthesia, the entire bodyof animals excluding theheadwas
shieldedwith lead andwas exposed to a 2-Gy daily dose of radiation
for five consecutive days starting on the eighth day after tumor cell
xenograft (days 8–12). Seven days following the first XRT treatment
and weekly thereafter (days 14, 21, and 28), animals were treated
eitherwithsterile salineorNSCs loadedwithOV(seebelow). Inbrief,
after anesthesia the mice were inoculated with 5 3 105 NSCs in
12 mL of sterile saline (given as three fractions at 5-min intervals)
via the nasal cavity as previously describedwith smallmodifications
(Balyasnikova et al., 2014). Allmicewere followed to assess their sur-
vival. Upon appearance of signs ofmorbidity,micewere euthanized
and whole brain tissues were excised immediately or after intracar-
diac perfusion with PBS or 4% paraformaldehyde, and embedded
in OCT compound (Sakura Finetek). Sections (10–20 mm) were cut,
air dried, and stained with H&E or processed for SDF-1 or hexon
fluorescence staining as detailed under Immunocytochemistry in
Supplemental Experimental Procedures.
Statistical Analysis
All statistical analyses were performed with Student’s t test using
GraphPad Prism 4 (GraphPad Software) unless specified otherwise.
The sample size for each group wasR3, where n represents biolog-
ical replicates unless otherwise indicated. All numerical data are
reported asmeans ± SEM.AKaplan-Meier survival curvewas gener-
ated and a log-rank test was applied to compare survival distri-
butions. For all survival experiments, n represents the number of
animals per group. All reported p values were two-sided and were
considered to be statistically significant at *p < 0.05, **p < 0.01,
and ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and two tables and can be found480 Stem Cell Reports j Vol. 7 j 471–482 j September 13, 2016with this article online at http://dx.doi.org/10.1016/j.stemcr.
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